X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Patent (123) 123
Journal Article (32) 32
Newspaper Article (11) 11
Book / eBook (8) 8
Conference Proceeding (3) 3
Magazine Article (2) 2
Publication (2) 2
Paper (1) 1
Trade Publication Article (1) 1
Video Recording (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
basic electric elements (90) 90
electric solid state devices not otherwise provided for (90) 90
electricity (90) 90
semiconductor devices (90) 90
general tagging of cross-sectional technologies spanning over several sections of the ipc (88) 88
general tagging of new technological developments (88) 88
reduction of greenhouse gas [ghg] emissions, related to energygeneration, transmission or distribution (88) 88
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (88) 88
technologies or applications for mitigation or adaptation againstclimate change (88) 88
climate change mitigation technologies in the production orprocessing of goods (33) 33
human necessities (33) 33
hygiene (33) 33
medical or veterinary science (33) 33
preparations for medical, dental, or toilet purposes (33) 33
specific therapeutic activity of chemical compounds ormedicinal preparations (18) 18
humans (14) 14
female (11) 11
male (11) 11
middle aged (11) 11
adult (9) 9
aged (9) 9
index medicus (8) 8
conversion or distribution of electric power (7) 7
generation (7) 7
generation of electric power by conversion of infra-redradiation, visible light or ultraviolet light, e.g. usingphotovoltaic [pv] modules (7) 7
oncology (7) 7
performing operations (7) 7
transporting (7) 7
aircraft (6) 6
aviation (6) 6
cosmonautics (6) 6
vehicles or equipment therefor (6) 6
analysis (5) 5
chemistry (5) 5
metallurgy (5) 5
organic chemistry (5) 5
peptides (5) 5
antineoplastic agents - adverse effects (4) 4
antiquities (4) 4
atrial fibrillation (4) 4
bible (4) 4
cancer (4) 4
care and treatment (4) 4
poster presentation (4) 4
aeroplanes (3) 3
aged, 80 and over (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
antiquités (3) 3
arrangements or mounting of power plants or propulsiontransmissions in aircraft (3) 3
article (3) 3
auxiliaries on vessels (3) 3
breast-cancer (3) 3
chemotherapy (3) 3
climate change mitigation technologies related totransportation (3) 3
dose-response relationship, drug (3) 3
electric equipment or propulsion of electrically-propelledvehicles (3) 3
electrodynamic brake systems for vehicles, in general (3) 3
equipment for fitting in or to aircraft (3) 3
flying suits (3) 3
helicopters (3) 3
interleukin-6 (3) 3
lighter-than air aircraft (3) 3
magnetic suspension or levitation for vehicles (3) 3
occupational health (3) 3
parachutes (3) 3
pharmacology & pharmacy (3) 3
photovoltaic cells (3) 3
public, environmental & occupational health (3) 3
related equipment (3) 3
research (3) 3
risk factors (3) 3
ships or other waterborne vessels (3) 3
studies (3) 3
technical subjects covered by former us classification (3) 3
technical subjects covered by former uspc (3) 3
usage (3) 3
vehicles in general (3) 3
women (3) 3
afuresertib (2) 2
akt inhibitor (2) 2
akt protein (2) 2
antibodies, monoclonal - administration & dosage (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - pharmacokinetics (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - pharmacokinetics (2) 2
bible. antiquities (2) 2
bible. criticism, interpretation, etc (2) 2
biblisk arkeologi (2) 2
biomarkers (2) 2
blasting (2) 2
cancer therapies (2) 2
cardiovascular magnetic resonance (2) 2
cell proliferation (2) 2
clinical trials (2) 2
combination therapy (2) 2
complications and side effects (2) 2
criticism, interpretation, etc (2) 2
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Gerstein Science - Stacks (2) 2
Knox College (Caven) - Stacks (2) 2
St. Augustine's Seminary - Stacks (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
UTL at Downsview - May be requested (2) 2
Mathematical Sciences - Stacks (1) 1
Media Commons - Audio Visual (1) 1
St. Augustine's Seminary - Reference (1) 1
St. Michael's College (John M. Kelly) - 3rd Floor (1) 1
Trinity College (John W Graham) - Oversize (1) 1
UofT at Mississauga - Mending (1) 1
UofT at Mississauga - Stacks (1) 1
Victoria University Emmanuel College - Reference (1) 1
Victoria University Emmanuel College - Stacks (1) 1
Victoria University Emmanuel College - Storage (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (174) 174
French (31) 31
German (27) 27
Chinese (14) 14
Japanese (4) 4
Korean (2) 2
Portuguese (2) 2
Spanish (2) 2
Hebrew (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Lundqvist, Andreas and van Hoef, Vincent and Zhang, Xiaonan and Wennerberg, Erik and Lorent, Julie and Witt, Kristina and Sanz, Laia Masvidal and Liang, Shuo and Murray, Shannon and Larsson, Ola and Kiessling, Rolf and Mao, Yumeng and Sidhom, John-William and Bessell, Catherine A and Havel, Jonathan and Schneck, Jonathan and Chan, Timothy A and Sachsenmeier, Eliot and Woods, David and Berglund, Anders and Ramakrishnan, Rupal and Sodre, Andressa and Weber, Jeffrey and Zappasodi, Roberta and Li, Yanyun and Qi, Jingjing and Wong, Philip and Sirard, Cynthia and Postow, Michael and Newman, Walter and Koon, Henry and Velcheti, Vamsidhar and Callahan, Margaret K and Wolchok, Jedd D and Merghoub, Taha and Lum, Lawrence G and Choi, Minsig and Thakur, Archana and Deol, Abhinav and Dyson, Gregory and Shields, Anthony and Haymaker, Cara and Uemura, Marc and Murthy, Ravi and James, Marihella and Wang, Daqing and Brevard, Julie and Monaghan, Catherine and Swann, Suzanne and Geib, James and Cornfeld, Mark and Chunduru, Srinivas and Agrawal, Sudhir and Yee, Cassian and Wargo, Jennifer and Patel, Sapna P and Amaria, Rodabe and Tawbi, Hussein and Glitza, Isabella and Woodman, Scott and Hwu, Wen-Jen and Davies, Michael A and Hwu, Patrick and Overwijk, Willem W and Bernatchez, Chantale and Diab, Adi and Massarelli, Erminia and Segal, Neil H and Ribrag, Vincent and Melero, Ignacio and Gangadhar, Tara C and Urba, Walter and Schadendorf, Dirk and Ferris, Robert L and Houot, Roch and Morschhauser, Franck and Logan, Theodore and Luke, Jason J and Sharfman, William and Barlesi, Fabrice and Ott, Patrick A and Mansi, Laura and Kummar, Shivaani and Salles, Gilles and Carpio, Cecilia and Meier, Roland and Krishnan, Suba and McDonald, Dan and Maurer, Matthew and Gu, Xuemin and Neely, Jaclyn and Suryawanshi, Satyendra and Levy, Ronald and Khushalani, Nikhil and Wu, Jennifer and Zhang, Jinyu and Basher, Fahmin and Rubinstein, Mark and Bucsek, Mark and Qiao, Guanxi and ...
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 11/2016, Volume 4, Issue S1
Journal Article
by Cheng, Ching-Yu and Schache, Maria and Ikram, M. Kamran and Ikram, M. Kamran and Young, Terri L and Young, Terri L and Guggenheim, Jeremy A and Guggenheim, Jeremy A and Vitart, Veronique and MacGregor, Stuart and Verhoeven, Virginie J.M and Verhoeven, Virginie J.M and Barathi, Veluchamy A and Liao, Jiemin and Hysi, Pirro G and Hysi, Pirro G and Bailey-Wilson, Joan E and St. Pourcain, Beate and Kemp, John P and McMahon, George and Timpson, Nicholas J and Evans, David M and Montgomery, Grant W and Mishra, Aniket and Wang, Jie Jin and Wang, Jie Jin and Wang, Ya Xing and Rochtchina, Elena and Polasek, Ozren and Wright, Alan F and Wright, Alan F and Amin, Najaf and van Leeuwen, Elisabeth M and Wilson, James F and Wilson, James F and Wilson, Joan E. Bailey and Pennell, Craig E and van Duijn, Cornelia M and de Jong, Paulus T.V.M and Vingerling, Johannes R and Zhou, Xin and Zhou, Xiangtian and Chen, Peng and Chen, Li Jia and Chen, Wei and Li, Ruoying and Tay, Wan-Ting and Zheng, Yingfeng and Zheng, D and Chew, Merwyn and Chew, Emily Y and Chew, Emily and Rahi, Jugnoo S and Yoshimura, Nagahisa and Yamashiro, Kenji and Miyake, Masahiro and Delcourt, Cécile and Maubaret, Cecilia and Williams, T and Williams, Katie M and Williams, Cathy and Northstone, Kate and Ring, Susan M and Davey-Smith, George and Craig, Jamie E and Burdon, Kathryn P and Fogarty, Rhys D and Iyengar, Sudha K and Igo, Robert P and Janmahasathian, Sarayut and Stambolian, Dwight and Lu, Yi and Jonas, Jost B and Xu, Liang and Saw, Seang-Mei and Baird, Paul N and Mitchell, Paul and Nangia, Vinay and Hayward, Caroline and Campbell, C and Campbell, Harry and Rudan, Igor and Vatavuk, Zoran and Paterson, Andrew D and Hosseini, S. Mohsen and Fondran, Jeremy R and Feng, Sheng and Klaver, Caroline C and Klaver, Caroline C.W and van Duijn, Cornelia M and Metspalu, Andres and Haller, Toomas and Mihailov, Evelin and Pärssinen, Olavi and Wedenoja, Juho and Wojciechowski, Robert and Pfeiffer, Norbert and Höhn, René and Pang, Chi Pui and Meitinger, Thomas and ... and Consortium Refractive Error Myopia and Fuchs Genetics Multictr Study Grp and Diabet Control Complications Trial and Wellcome Trust Case Control Consor and Fuchs' Genetics Multi-Center Study Group and Consortium for Refractive Error and Myopia and Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions, and Complications Research Group and Wellcome Trust Case Control Consortium 2
The American Journal of Human Genetics, ISSN 0002-9297, 08/2013, Volume 93, Issue 2, pp. 264 - 277
Journal Article
Pediatric Blood & Cancer, ISSN 1545-5009, 05/2017, Volume 64, Issue 5, pp. e26325 - n/a
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2010, Volume 28, Issue 23, pp. 3701 - 3708
Purpose Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab... 
MULTIPLE-MYELOMA | RECEPTOR | THERAPY | ONCOLOGY | INTERLEUKIN-6 | CANCER | Young Adult | Castleman Disease - drug therapy | Humans | Middle Aged | Interleukin-6 - immunology | Adult | Antibodies, Monoclonal - therapeutic use | Female | Male | Aged | Index Medicus
Journal Article
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, ISSN 1532-429X, 01/2019, Volume 21, Issue 1, pp. 2 - 12
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2015, Volume 75, Issue 1, pp. 183 - 189
To identify the maximum tolerated dose (MTD) and recommended Phase II dose of MEK/AKT inhibitor combination of trametinib and afuresertib.Eligibility criteria... 
Medicine & Public Health | MEK Inhibitor | Afuresertib | Oncology | Cancer Research | Pharmacology/Toxicology | Combination therapy | AKT Inhibitor | Trametinib | MEK inhibitor | AKT inhibitor | MELANOMA | ONCOLOGY | PATHWAY | MUTATION | PHARMACOLOGY & PHARMACY | HUMAN CANCER | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Thiophenes - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Early Termination of Clinical Trials | Pyridones - administration & dosage | Multiple Myeloma - drug therapy | Neoplasms - blood | Antineoplastic Agents - adverse effects | Adult | Female | Antineoplastic Agents - pharmacokinetics | Multiple Myeloma - enzymology | Pyrazoles - pharmacokinetics | Multiple Myeloma - blood | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasms - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Thiophenes - pharmacokinetics | Pyrazoles - administration & dosage | Pyrimidinones - pharmacokinetics | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Pyridones - therapeutic use | Pyrimidinones - administration & dosage | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Pyridones - adverse effects | Cohort Studies | Complications and side effects | Medical research | Care and treatment | Type 1 diabetes | Analysis | Gastrointestinal diseases | Multiple myeloma | Melanoma | Medicine, Experimental | Aspartate | Nausea | Tumors | Index Medicus
Journal Article
Investigational New Drugs, ISSN 0167-6997, 6/2013, Volume 31, Issue 3, pp. 669 - 676
Purpose Siltuximab is a chimeric, anti-interleukin-6 monoclonal antibody with potential therapeutic benefit in castration-resistant prostate cancer (CRPC)... 
Siltuximab | C-reactive protein | Medicine & Public Health | Docetaxel | Oncology | Pharmacology/Toxicology | Prostate cancer | Interleukin-6 | PLASMA | PHARMACOKINETICS | ONCOLOGY | DISEASE | DOWN-REGULATION | PHARMACOLOGY & PHARMACY | CARCINOMA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - administration & dosage | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Aged, 80 and over | Prostatic Neoplasms - blood | Adult | Antineoplastic Agents - pharmacokinetics | C-Reactive Protein - analysis | Prostatic Neoplasms - drug therapy | Taxoids - adverse effects | Prostatic Neoplasms - pathology | Antibodies, Monoclonal - pharmacokinetics | Prostate-Specific Antigen - blood | Orchiectomy | Taxoids - pharmacokinetics | Taxoids - administration & dosage | Antibodies, Monoclonal - administration & dosage | Interleukin-6 - immunology | Aged | Antimitotic agents | Patient outcomes | Dosage and administration | Research | Drug therapy, Combination | Antineoplastic agents | Drug therapy | Studies | Proteins | Prescription drugs | Medical research | Chemotherapy | Statistical analysis | Research & development--R&D | Monoclonal antibodies | Pharmacology | Metastasis | Cancer therapies | Index Medicus
Journal Article
Journal of Cardiovascular Magnetic Resonance, ISSN 1532-429X, 01/2014, Volume 16, Issue S1, pp. P152 - P152
  Doc number: P152 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2011, Volume 152, Issue 5, pp. 579 - 592
Signalling through the interleukin (IL)‐6 pathway induces proliferation and drug resistance of multiple myeloma cells. We therefore sought to determine whether... 
multiple myeloma | siltuximab | Akt | Interleukin‐6 | melphalan | Siltuximab | Melphalan | Multiple myeloma | Interleukin-6 | SURVIVAL | APOPTOSIS | BONE-MARROW | CELL-DEATH | TARGETED INHIBITION | IN-VIVO | ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY | HEMATOLOGY | PROTEASOME INHIBITORS | DEPENDENT MECHANISM | BCL-2 FAMILY | Cell Survival - drug effects | Interleukin-6 - antagonists & inhibitors | Apoptosis - drug effects | Antibodies, Monoclonal - pharmacology | Humans | bcl-2-Associated X Protein - metabolism | Multiple Myeloma - metabolism | Neoplasm Proteins - metabolism | bcl-2 Homologous Antagonist-Killer Protein - metabolism | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Plasma Cells - drug effects | Melphalan - administration & dosage | Multiple Myeloma - pathology | Signal Transduction - drug effects | Antibodies, Monoclonal - administration & dosage | Melphalan - pharmacology | Tumor Cells, Cultured | Proto-Oncogene Proteins c-akt - metabolism | BH3 Interacting Domain Death Agonist Protein - metabolism | Drug Screening Assays, Antitumor | Interleukins | Cell death | Leukemia | Stem cells | Monoclonal antibodies | Lymphomas | Models | Amyloidosis | Transplantation | Drug resistance | Cell proliferation | Phosphorylation | Translation | AKT protein | Cytotoxicity | Monoclonal gammopathy | Tumor cell lines | BAK protein | Caspase-3 | phosphoinositides | Caspase-8 | Interleukin 6 | Signal transduction | stromal cells | Caspase-9 | Plasma cells | p70 S6 kinase | Apoptosis
Journal Article